Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab Phase 2 in Plaque Psoriasis
NCT02899988Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2016
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of mirikizumab in plaque psoriasis (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants With a >=90% Improvement in Psoriasis Area and Severity Index at 16 weeks. Started Sep 2016; status: completed.
02
Drugs
mirikizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02899988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02899988.